Xencor Inc. (XNCR) announced Tuesday morning that it has entered into a collaboration and license agreement with Novartis for the development of XmAb14045 and XmAb13676. Xencor will receive a $150 million upfront payment plus milestone payments and royalties.
from RTT - Before the Bell http://ift.tt/298wOos
via IFTTT
No comments:
Post a Comment